go to The Japanese Society of Gastroenterological Surgery official home page The Japanese Journal of Gastroenterological Surgery Online Journal
go to main navigation
go to Home
go to Current Issue
go to Past Issue
go to Article Search
Abstract go to Japanese page English
Vol.32 No.4 1999 April [Table of Contents] [Full text ( PDF 34KB)]
INVITED LECTURES

Prediction of Intrahepatic Recurrence of Hepatocellular Carcinoma and Chemotherapy with Systemic Interferon α Administration

Masato Sakon, Hiroaki Nagano, Koji Umeshita, Shinichi Kishimoto, Hidetoshi Eguchi, Atsushi Miyamoto, Keizo Dohno, Shoji Nakamori, Mitsukazu Gotoh and Morito Monden

Department of Surgery II, Osaka University Medical School

Adjuvant therapy after surgical resection of hepatocellular carcinoma (HCC) should be tried based on the prediction of intrahepatic recurrence pattern. The purpose of this study was to identify patients with intrahepatic recurrence due to the residual intrahepatic metastatic foci (Rec: im) or multicentric carcinogenesis (Rec: mc) and to evaluate the effectiveness of combination therapy with an anticancer drug and interferon α (IFNα ). The disease-free survival curve was obtained by the Kaplan-Meier method in 294 patients with resectable HCC. The regression line (Y=-aX+b) was drawn by SAS LIFE TEST PROCEDURE in the early (Y1; within two years: Rec: im+Rec: mc) and late (Y2; 4 years later: Rec: mc) periods and the incidence of Rec: im (b1-b2) was determined. The incidence of Rec: im in stage 1 was 40% in relative curative cases, and in stage 2 were 22% and 42% in relative curative and relative noncurative cases, respectively. In stage 3 and 4, all patients but one had recurrence within 4 years. Tumor marker levels were markedly decreased in 4 of 5 patients following the combination therapy of anticancer drug and IFNα . In conclusion, Rec: im was frequent, and therefore, adjuvant therapy was indicated in patients with stage 1 (relative curative), stage 2 (relative noncurative), stage 3 and stage 4. A combination of chemotherapy and systemic IFNα administration may be a promising postoperative adjuvant therapy.

Key words
hepatocellular carcinoma, recurrence, interferon-α

Jpn J Gastroenterol Surg 32: 1080-1083, 1999

Reprint requests
Masato Sakon Department of Surgery II, Osaka University Medical School 2-2 Yamadaoka, Suita, Osaka, 565-0871 JAPAN

Accepted
January 27, 1999

go to download site To read the PDF file you will need Abobe Reader installed on your computer.
return to the head of this page
back to main navigation
Copyright © The Japanese Society of Gastroenterological Surgery